{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:44:08Z","timestamp":1793317448098,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"29","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.biomaterials.2012.06.026","type":"journal-article","created":{"date-parts":[[2012,7,12]],"date-time":"2012-07-12T04:47:05Z","timestamp":1342068425000},"page":"7164-7173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":175,"title":["Alendronate coated poly-lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic breast cancer"],"prefix":"10.1016","volume":"33","author":[{"given":"Sanjay I.","family":"Thamake","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangram L.","family":"Raut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zygmunt","family":"Gryczynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalendu P.","family":"Ranjan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamboor K.","family":"Vishwanatha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biomaterials.2012.06.026_bib1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/978-3-642-00477-3_2","article-title":"Nanoparticle technologies for cancer therapy","volume":"197","author":"Alexis","year":"2010","journal-title":"Handb Exp Pharmacol"},{"issue":"2","key":"10.1016\/j.biomaterials.2012.06.026_bib2","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1053\/j.seminoncol.2010.10.002","article-title":"Implications of bone metastases and the benefits of bone-targeted therapy","volume":"37","author":"Lipton","year":"2010","journal-title":"Semin Oncol"},{"key":"10.1016\/j.biomaterials.2012.06.026_bib3","first-page":"42","article-title":"New strategies to prevent and manage bone complications in cancer","volume":"9","author":"Lipton","year":"2011","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.biomaterials.2012.06.026_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2012.01.012","article-title":"Targeting polymer therapeutics to bone","author":"Low","year":"2012","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.biomaterials.2012.06.026_bib5","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1158\/1078-0432.CCR-07-2223","article-title":"The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance","volume":"14","author":"Meads","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.biomaterials.2012.06.026_bib6","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","article-title":"Metastasis to bone: causes, consequences and therapeutic opportunities","volume":"2","author":"Mundy","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.biomaterials.2012.06.026_bib7","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nrc2618","article-title":"Microenvironmental regulation of metastasis","volume":"9","author":"Joyce","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.biomaterials.2012.06.026_bib8","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1089\/jpm.2009.9633","article-title":"Therapeutic guidelines for the treatment of bone metastasis: a report from the American College of Radiology appropriateness criteria expert panel on radiation oncology","volume":"12","author":"Janjan","year":"2009","journal-title":"J\u00a0Palliat Med"},{"key":"10.1016\/j.biomaterials.2012.06.026_bib9","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1158\/1078-0432.CCR-07-1441","article-title":"Therapeutic nanoparticles for drug delivery in cancer","volume":"14","author":"Cho","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.biomaterials.2012.06.026_bib10","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/nrc1566","article-title":"Cancer nanotechnology: opportunities and challenges","volume":"5","author":"Ferrari","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.biomaterials.2012.06.026_bib11","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/00000421-200212001-00002","article-title":"Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis","volume":"25","author":"Green","year":"2002","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.biomaterials.2012.06.026_bib12","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.bone.2007.03.002","article-title":"Determinants of structure\u2013function relationships among bisphosphonates","volume":"40","author":"Russell","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.biomaterials.2012.06.026_bib13","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bone.2005.05.003","article-title":"Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite","volume":"38","author":"Nancollas","year":"2006","journal-title":"Bone"},{"key":"10.1016\/j.biomaterials.2012.06.026_bib14","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jconrel.2007.06.003","article-title":"Design of surface-modified poly(D, L-lactide-co-glycolide) nanoparticles for targeted drug delivery to bone","volume":"122","author":"Choi","year":"2007","journal-title":"J\u00a0Control Release"},{"key":"10.1016\/j.biomaterials.2012.06.026_bib15","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ijpharm.2006.11.024","article-title":"Bone targeting potential of bisphosphonate-targeted liposomes. Preparation, characterization and hydroxyapatite binding in\u00a0vitro","volume":"331","author":"Hengst","year":"2007","journal-title":"Int J Pharm"},{"key":"10.1016\/j.biomaterials.2012.06.026_bib16","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.biomaterials.2007.12.022","article-title":"Biocompatibility of poly(D, L-lactide-co-glycolide) nanoparticles conjugated with alendronate","volume":"29","author":"Cenni","year":"2008","journal-title":"Biomaterials"},{"key":"10.1016\/j.biomaterials.2012.06.026_bib17","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.addr.2004.12.011","article-title":"Bone-targeting macromolecular therapeutics","volume":"57","author":"Wang","year":"2005","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.biomaterials.2012.06.026_bib18","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2174\/156800910793605767","article-title":"Bone-targeted doxorubicin-loaded nanoparticles as a tool for the treatment of skeletal metastases","volume":"10","author":"Salerno","year":"2010","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.biomaterials.2012.06.026_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-0-387-74039-3_1","article-title":"Overview of resistance to systemic therapy in patients with breast cancer","volume":"608","author":"Gonzalez-Angulo","year":"2007","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.biomaterials.2012.06.026_bib20","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000099202","article-title":"The chemopreventive polyphenol curcumin prevents hematogenous breast cancer metastases in immunodeficient mice","volume":"19","author":"Bachmeier","year":"2007","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.biomaterials.2012.06.026_bib21","doi-asserted-by":"crossref","first-page":"4978","DOI":"10.1158\/1078-0432.CCR-09-3293","article-title":"A\u00a0proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes","volume":"16","author":"Jones","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.biomaterials.2012.06.026_bib22","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.molonc.2008.09.006","article-title":"Curcumin in combination with bortezomib synergistically induced apoptosis in human multiple myeloma U266 cells","volume":"2","author":"Park","year":"2008","journal-title":"Mol Oncol"},{"key":"10.1016\/j.biomaterials.2012.06.026_bib23","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1158\/1535-7163.MCT-08-0905","article-title":"Curcumin circumvents chemoresistance in\u00a0vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model","volume":"8","author":"Sung","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.biomaterials.2012.06.026_bib24","doi-asserted-by":"crossref","first-page":"5940","DOI":"10.4049\/jimmunol.172.10.5940","article-title":"Curcumin (diferuloylmethane) inhibits receptor activator of NF-kappa B ligand-induced NF-kappa B activation in osteoclast precursors and suppresses osteoclastogenesis","volume":"172","author":"Bharti","year":"2004","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.biomaterials.2012.06.026_bib25","doi-asserted-by":"crossref","first-page":"035101","DOI":"10.1088\/0957-4484\/22\/3\/035101","article-title":"Surface functionalization of PLGA nanoparticles by non-covalent insertion of a homo-bifunctional spacer for active targeting in cancer therapy","volume":"22","author":"Thamake","year":"2011","journal-title":"Nanotechnology"},{"key":"10.1016\/j.biomaterials.2012.06.026_bib26","first-page":"3867","article-title":"Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy","volume":"29","author":"Mukerjee","year":"2009","journal-title":"Anticancer Res"},{"key":"10.1016\/j.biomaterials.2012.06.026_bib27","doi-asserted-by":"crossref","first-page":"295104","DOI":"10.1088\/0957-4484\/22\/29\/295104","article-title":"A\u00a0sustained release formulation of chitosan modified PLCL:poloxamer blend nanoparticles loaded with optical agent for animal imaging","volume":"22","author":"Ranjan","year":"2011","journal-title":"Nanotechnology"},{"key":"10.1016\/j.biomaterials.2012.06.026_bib28","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3109\/10611861003622560","article-title":"Bisphosphonate-coated BSA nanoparticles lack bone targeting after systemic administration","volume":"18","author":"Wang","year":"2010","journal-title":"J\u00a0Drug Target"},{"key":"10.1016\/j.biomaterials.2012.06.026_bib29","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ejps.2009.02.019","article-title":"Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer","volume":"37","author":"Shaikh","year":"2009","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.biomaterials.2012.06.026_bib30","doi-asserted-by":"crossref","first-page":"395102","DOI":"10.1088\/0957-4484\/21\/39\/395102","article-title":"The formulation, characterization and in\u00a0vivo evaluation of a magnetic carrier for brain delivery of NIR dye","volume":"21","author":"Raut","year":"2010","journal-title":"Nanotechnology"},{"key":"10.1016\/j.biomaterials.2012.06.026_bib31","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejpb.2006.12.020","article-title":"Optimization of iron oxide nanoparticles encapsulation within poly(d, l-lactide-co-glycolide) sub-micron particles","volume":"67","author":"Okassa","year":"2007","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.biomaterials.2012.06.026_bib32","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1166\/jbn.2007.010","article-title":"Polymeric nanoparticles for sustained down-regulation of annexin A2 lead to reduction in proliferation and migration of prostate cancer cells","volume":"3","author":"Braden","year":"2007","journal-title":"J\u00a0Biomed Nanotechnol"},{"key":"10.1016\/j.biomaterials.2012.06.026_bib33","first-page":"196","article-title":"Characterization of nanoparticle-mediated drug delivery to NB4: feasibility of nanoparticle use for cells in suspension and blood diseases","volume":"4","author":"Kafka","year":"2008","journal-title":"J\u00a0Biomed Nanotechnol"},{"key":"10.1016\/j.biomaterials.2012.06.026_bib34","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/00912709922007958","article-title":"Pharmacokinetics of intravenous alendronate","volume":"39","author":"Cocquyt","year":"1999","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.biomaterials.2012.06.026_bib35","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1021\/jp047550u","article-title":"Enhanced emission of nile red fluorescent nanoparticles embedded in hybrid sol-gel glasses","volume":"109","author":"Ferrer","year":"2005","journal-title":"J\u00a0Phys Chem B"},{"key":"10.1016\/j.biomaterials.2012.06.026_bib36","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1083\/jcb.100.3.965","article-title":"Nile red: a selective fluorescent stain for intracellular lipid droplets","volume":"100","author":"Greenspan","year":"1985","journal-title":"J\u00a0Cell Biol"},{"key":"10.1016\/j.biomaterials.2012.06.026_bib37","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1021\/mp800137z","article-title":"Intracellular drug delivery by poly(lactic-co-glycolic acid) nanoparticles, revisited","volume":"6","author":"Xu","year":"2009","journal-title":"Mol Pharm"},{"key":"10.1016\/j.biomaterials.2012.06.026_bib38","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1146\/annurev.med.57.042905.122625","article-title":"Bortezomib: proteasome inhibition as an effective anticancer therapy","volume":"57","author":"Richardson","year":"2006","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.biomaterials.2012.06.026_bib39","doi-asserted-by":"crossref","first-page":"6847","DOI":"10.1158\/1078-0432.CCR-04-0744","article-title":"Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance","volume":"10","author":"Sharma","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.biomaterials.2012.06.026_bib40","doi-asserted-by":"crossref","first-page":"7829","DOI":"10.1073\/pnas.0601643103","article-title":"The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs","volume":"103","author":"Kavanagh","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biomaterials.2012.06.026_bib41","first-page":"1894","article-title":"Pharmacodynamic and pharmacokinetic study of oral curcuma extract in patients with colorectal cancer","volume":"7","author":"Sharma","year":"2001","journal-title":"Clin Cancer Res"}],"container-title":["Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014296121200662X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014296121200662X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T15:44:07Z","timestamp":1758901447000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014296121200662X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":41,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S014296121200662X"],"URL":"https:\/\/doi.org\/10.1016\/j.biomaterials.2012.06.026","relation":{},"ISSN":["0142-9612"],"issn-type":[{"value":"0142-9612","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alendronate coated poly-lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic breast cancer","name":"articletitle","label":"Article Title"},{"value":"Biomaterials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biomaterials.2012.06.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}